Revisiting the role of surgery in the treatment of Graves’ disease

Oded Cohen; Ohad Ronen; Avi Khafif; Juan P. Rodrigo; Ricard Simo; Pia Pace-Asciak; Gregory Randolph; Lauge H. Mikkelsen; Luiz P. Kowalski; Kerry D. Olsen; Alvaro Sanabria; Ralph P. Tufano; Silvia Babighian; Ashok R. Shaha; Mark Zafereo; Alfio Ferlito

doi:10.1111/cen.14653

Revisiting the role of surgery in the treatment of Graves’ disease

Oded Cohen
, Ohad Ronen
, Avi Khafif
, Juan P. Rodrigo
, Ricard Simo
, Pia Pace-Asciak
, Gregory Randolph
, Lauge H. Mikkelsen
, Luiz P. Kowalski
, Kerry D. Olsen
, Alvaro Sanabria
, Ralph P. Tufano
, Silvia Babighian
, Ashok R. Shaha
, Mark Zafereo
, Alfio Ferlito

Bar-Ilan University - Azrieli Faculty of Medicine

Yale University
Ben-Gurion University of the Negev
Hospital Universitario Central de Asturias
Guy's and St Thomas' NHS Foundation Trust
University of Toronto
Harvard University
University of Copenhagen
Universidade de São Paulo
A.C.Camargo Cancer Center
Mayo Clinic Rochester, MN
Universidad de Antioquia
CEXCA Centro de Excelencia en Enfermedades de Cabeza y Cuello
Sarasota Memorial Health Care System
Johns Hopkins University
Azienda Ospedaliera di Padova
Memorial Sloan-Kettering Cancer Center
University of Texas MD Anderson Cancer Center
International Head and Neck Scientific Group

Research output: Contribution to journal › Review article › peer-review

18 Scopus citations

Abstract

Graves’ disease (GD) can be managed by antithyroid drugs (ATD), radioactive iodine (RAI) and surgery. Thyroidectomy offers the highest success rates for both primary and persistent disease, yet it is the least recommended or utilized option reaching <1% for primary disease and <25% for persistent disease. Several surveys have found surgery to be the least recommended by endocrinologists worldwide. With the development of remote access thyroidectomies and intraoperative nerve monitoring of the recurrent laryngeal nerve, combined with current knowledge of possible risks associated with RAI or failure of ATDs, revaluation of the benefit to harm ratio of surgery in the treatment of GD is warranted. The aim of this review is to discuss possible reasons for the low proportion of surgery in the treatment of GD, emphasizing an evidence-based approach to the clinicians’ preferences for surgical referrals, surgical indications and confronting traditional reasons and concerns relating to the low referral rate with up-to-date data.

Original language	English
Pages (from-to)	747-757
Number of pages	11
Journal	Clinical Endocrinology
Volume	96
Issue number	6
DOIs	https://doi.org/10.1111/cen.14653
State	Published - Jun 2022

Bibliographical note

Publisher Copyright:
© 2021 John Wiley & Sons Ltd.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Graves' disease
head and neck
hyperthyroidism
surgery

Access to Document

10.1111/cen.14653

Cite this

Cohen, O., Ronen, O., Khafif, A., Rodrigo, J. P., Simo, R., Pace-Asciak, P., Randolph, G., Mikkelsen, L. H., Kowalski, L. P., Olsen, K. D., Sanabria, A., Tufano, R. P., Babighian, S., Shaha, A. R., Zafereo, M., & Ferlito, A. (2022). Revisiting the role of surgery in the treatment of Graves’ disease. Clinical Endocrinology, 96(6), 747-757. https://doi.org/10.1111/cen.14653

@article{4c030eeee94d44bea98cd199f5a29c3d,

title = "Revisiting the role of surgery in the treatment of Graves{\textquoteright} disease",

abstract = "Graves{\textquoteright} disease (GD) can be managed by antithyroid drugs (ATD), radioactive iodine (RAI) and surgery. Thyroidectomy offers the highest success rates for both primary and persistent disease, yet it is the least recommended or utilized option reaching <1\% for primary disease and <25\% for persistent disease. Several surveys have found surgery to be the least recommended by endocrinologists worldwide. With the development of remote access thyroidectomies and intraoperative nerve monitoring of the recurrent laryngeal nerve, combined with current knowledge of possible risks associated with RAI or failure of ATDs, revaluation of the benefit to harm ratio of surgery in the treatment of GD is warranted. The aim of this review is to discuss possible reasons for the low proportion of surgery in the treatment of GD, emphasizing an evidence-based approach to the clinicians{\textquoteright} preferences for surgical referrals, surgical indications and confronting traditional reasons and concerns relating to the low referral rate with up-to-date data.",

keywords = "Graves' disease, head and neck, hyperthyroidism, surgery",

author = "Oded Cohen and Ohad Ronen and Avi Khafif and Rodrigo, \{Juan P.\} and Ricard Simo and Pia Pace-Asciak and Gregory Randolph and Mikkelsen, \{Lauge H.\} and Kowalski, \{Luiz P.\} and Olsen, \{Kerry D.\} and Alvaro Sanabria and Tufano, \{Ralph P.\} and Silvia Babighian and Shaha, \{Ashok R.\} and Mark Zafereo and Alfio Ferlito",

note = "Publisher Copyright: {\textcopyright} 2021 John Wiley \& Sons Ltd.",

year = "2022",

month = jun,

doi = "10.1111/cen.14653",

language = "אנגלית",

volume = "96",

pages = "747--757",

journal = "Clinical Endocrinology",

issn = "0300-0664",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "6",

}

TY - JOUR

T1 - Revisiting the role of surgery in the treatment of Graves’ disease

AU - Cohen, Oded

AU - Ronen, Ohad

AU - Khafif, Avi

AU - Rodrigo, Juan P.

AU - Simo, Ricard

AU - Pace-Asciak, Pia

AU - Randolph, Gregory

AU - Mikkelsen, Lauge H.

AU - Kowalski, Luiz P.

AU - Olsen, Kerry D.

AU - Sanabria, Alvaro

AU - Tufano, Ralph P.

AU - Babighian, Silvia

AU - Shaha, Ashok R.

AU - Zafereo, Mark

AU - Ferlito, Alfio

PY - 2022/6

Y1 - 2022/6

N2 - Graves’ disease (GD) can be managed by antithyroid drugs (ATD), radioactive iodine (RAI) and surgery. Thyroidectomy offers the highest success rates for both primary and persistent disease, yet it is the least recommended or utilized option reaching <1% for primary disease and <25% for persistent disease. Several surveys have found surgery to be the least recommended by endocrinologists worldwide. With the development of remote access thyroidectomies and intraoperative nerve monitoring of the recurrent laryngeal nerve, combined with current knowledge of possible risks associated with RAI or failure of ATDs, revaluation of the benefit to harm ratio of surgery in the treatment of GD is warranted. The aim of this review is to discuss possible reasons for the low proportion of surgery in the treatment of GD, emphasizing an evidence-based approach to the clinicians’ preferences for surgical referrals, surgical indications and confronting traditional reasons and concerns relating to the low referral rate with up-to-date data.

AB - Graves’ disease (GD) can be managed by antithyroid drugs (ATD), radioactive iodine (RAI) and surgery. Thyroidectomy offers the highest success rates for both primary and persistent disease, yet it is the least recommended or utilized option reaching <1% for primary disease and <25% for persistent disease. Several surveys have found surgery to be the least recommended by endocrinologists worldwide. With the development of remote access thyroidectomies and intraoperative nerve monitoring of the recurrent laryngeal nerve, combined with current knowledge of possible risks associated with RAI or failure of ATDs, revaluation of the benefit to harm ratio of surgery in the treatment of GD is warranted. The aim of this review is to discuss possible reasons for the low proportion of surgery in the treatment of GD, emphasizing an evidence-based approach to the clinicians’ preferences for surgical referrals, surgical indications and confronting traditional reasons and concerns relating to the low referral rate with up-to-date data.

KW - Graves' disease

KW - head and neck

KW - hyperthyroidism

KW - surgery

UR - https://www.scopus.com/pages/publications/85121735496

U2 - 10.1111/cen.14653

DO - 10.1111/cen.14653

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???

C2 - 34954838

AN - SCOPUS:85121735496

SN - 0300-0664

VL - 96

SP - 747

EP - 757

JO - Clinical Endocrinology

JF - Clinical Endocrinology

IS - 6

ER -

Revisiting the role of surgery in the treatment of Graves’ disease

Abstract

Bibliographical note

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this